Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Rang in aandelen #105
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery,... AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Aandeelprijs
$193.62
Marktkapitalisatie
$150.08B
Verandering (1 dag)
2.76%
Verandering (1 jaar)
184.69%
Land
GB
Handel AstraZeneca PLC (AZN)

Categorie

Dividendgeschiedenis van AstraZeneca PLC (AZN)
AstraZeneca PLC (aandelsymbool: AZN) heeft in totaal 67 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: $33.24
Dividendrendement (TTM): 0.0161
Dividendbetalingen voor AstraZeneca PLC (AZN) van 1993 tot 2026
Jaarlijkse dividendbetalingen
Jaar Dividend (aangepast voor aandelensplitsingen) Wijzigen
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 1.72%
2023 $1.45 0.00%
2022 $1.45 3.57%
2021 $1.40 0.00%
2020 $1.40 0.00%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 0.00%
2015 $1.40 0.00%
2014 $1.40 0.00%
2013 $1.40 -1.75%
2012 $1.43 5.56%
2011 $1.35 12.03%
2010 $1.21 15.31%
2009 $1.05 10.00%
2008 $0.95 8.57%
2007 $0.875 24.11%
2006 $0.705 37.56%
2005 $0.5125 22.75%
2004 $0.4175 7.46%
2003 $0.3885 -0.13%
2002 $0.389 0.00%
2001 $0.389 -57.97%
2000 $0.9255 205.45%
1999 $0.303 -23.77%
1998 $0.3975 11.38%
1997 $0.3569 44.49%
1996 $0.247 -13.97%
1995 $0.2871 10.47%
1994 $0.2599 169.33%
1993 $0.0965 0.00%
Lijst van alle dividendbetalingen
Jaar Dividend Wijzigen
2026 (TTM) $2.17 38.88%
2025 $1.57 6.10%
2024 $1.48 3.15%
2023 $1.43 0.70%
2022 $1.42 2.16%
2021 $1.39 0.00%
2020 $1.39 -0.71%
2019 $1.40 0.00%
2018 $1.40 0.00%
2017 $1.40 0.00%
2016 $1.40 -40.43%
2015 $2.35 -16.07%
2014 $2.80 0.00%
2013 $2.80 -1.75%
2012 $2.85 5.56%
2011 $2.70 12.03%
2010 $2.41 15.31%
2009 $2.09 10.00%
2008 $1.90 8.57%
2007 $1.75 24.11%
2006 $1.41 37.56%
2005 $1.03 22.75%
2004 $0.835 7.46%
2003 $0.777 -0.13%
2002 $0.778 0.00%
2001 $0.778 -57.97%
2000 $1.85 205.45%
1999 $0.606 -66.68%
1998 $1.82 -15.04%
1997 $2.14 44.47%
1996 $1.48 -13.99%
1995 $1.72 10.52%
1994 $1.56 169.26%
1993 $0.579 0.00%
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
Bedrijf Aantal dividendbetalingen Land
215.00%
US
225.00%
US
53.00%
US
32.00%
CH
223.00%
US